Anti-vascular endothelial growth factor therapy for breast cancer: Can we pick the winners?

Journal of Clinical Oncology

Volumn 29, Issue 18, 2011, Pages 2444-2447

  Schneider, Bryan P ^a   Sledge Jr , George W ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; SUNITINIB; VASCULOTROPIN INHIBITOR;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DRUG INDICATION; EDITORIAL; HUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; GUIDELINES AS TOPIC; HUMANS; IMIDAZOLES; INDAZOLES; INDIVIDUALIZED MEDICINE; MULTICENTER STUDIES AS TOPIC; NEOPLASM PROTEINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RESEARCH DESIGN; TAXOIDS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79959304867     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.34.9266     Document Type: Editorial

References (30)

1. Miller KD, Chap LI, Holmes FA, et al: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792-799, 2005 (Pubitemid 46224178)
2. Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676, 2007
3. Miles D, Chan A, Romieu G, et al: Final overall survival (OS) results from the randomised, double-blind, placebo-controlled, phase III AVADO study of bevacizumab (BV) plus docetaxel (D) compared with placebo (PL) plus D for the first-line treatment of locally recurrent (LR) or metastatic breast cancer (mBC). Cancer Res 69:495s, 2009
4. Robert N, Dieras V, Glaspy J, et al: RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 27:42s, 2009 (suppl; abstr 1005)
5. Crown J, Dieras V, Staroslawska E, et al: Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC). J Clin Oncol 28:18s, 2010 (suppl; abstr LBA1011)
6. Bergh J, Greil R, Voytko N, et al: Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC). J Clin Oncol 28:18s, 2010 (suppl; abstr LBA1010)
7. Ebos JM, Lee CR, Christensen JG, et al: Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci U S A 104:17069-17074, 2007 (Pubitemid 350210993)
8. Paez-Ribes M, Allen E, Hudock J, et al: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15:220-231, 2009
9. Pegram MD, Pietras R, Bajamonde A, et al: Targeted therapy: Wave of the future. J Clin Oncol 23:1776-1781, 2005 (Pubitemid 46211429)
10. Genentech: Submission of Genentech Inc in response to the Food and Drug Administration's notice of opportunity for a hearing and proposal to withdraw approval of AVASTIN (bevacizumab) in combination with weekly paclitaxel for the first-line treatment of patients with metastatic breast cancer. 2011. http://www.gene.com/gene/news/news-events/avastin/documents/NOOH-Prim-Sub-Doc- FINAL-16JAN2011.pdf
11. Schneider BP, Wang M, Radovich M, et al: Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26:4672-4678, 2008
12. Kim J, Vaziri S, Elson P, et al: VEGF single nucleotide polymorphisms (SNPs) and correlation to sunitinib-induced hypertension (HTN) in metastatic renal cell carcinoma (mRCC) patients (pts). J Clin Oncol 27:15s, 2009 (suppl; abstr 5005)
13. Kim J, Vaziri S, Elson P, et al: Role of VEGF and VEGFR2 single nucleotide polymorphisms (SNPs) in predicting treatment-induced hypertension (HTN) and clinical outcome (CO) in metastatic clear cell RCC (mccRCC) patients (pts) treated with sunitinib. J Clin Oncol 28:15s, 2010 (suppl; abstr 4629)
14. Koutras A, Antonacopoulou A, Fostira F, et al: Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab in the first-line setting. J Clin Oncol 28:15s, 2010 (suppl; abstr 3587)
15. Lambrechts D, Delmar P, Buysschaert I, et al: VEGFR-1 polymorphisms as potential predictors of clinical outcome in bevacizumab-treated patients with metastatic pancreatic cancer Eur J Cancer Supplements 7:10, 2009
16. Schneider BP, Radovich M, Miller KD: The role of vascular endothelial growth factor genetic variability in cancer. Clin Cancer Res 15:5297-5302, 2009
17. Zhang W, Dahlberg S, Yang D, et al: Genetic variants in angiogenesis pathway associated with clinical outcome in NSCLC patients (pts) treated with bevacizumab in combination with carboplatin and paclitaxel: Subset pharmacogenetic analysis of ECOG 4599. J Clin Oncol 27:15s, 2009 (suppl; abstr 8032)
18. Zhang W, Lee J, Schiller J, et al: Use of germline polymorphisms in VEGF to predict tumor response and progression-free survival in non-small-cell lung cancer (NSCLC) patients treated with sorafenib: Subset pharmacogenetic analysis of Eastern Cooperative Oncology Group (ECOG) trial E2501. J Clin Oncol 28:15s, 2010 (suppl; abstr 7607)
19. Jain RK, Duda DG, Willett CG, et al: Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 6:327-338, 2009
20. Jubb AM, Harris AL: Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 11:1172-1183
21. Dahlberg S, Sandler A, Brahmer J, et al: Clinical course of advanced non-small-cell lung cancer (NSCLC) patients (pts) experiencing hypertension (HTN) during treatment (TX) with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P) on E4599. J Clin Oncol 27:15s, 2009 (suppl; abstr 8042)
22. Goodwin R, Seymour L, Ding K, et al: Hypertension (HTN) in National Cancer Institute of Canada Clinical Trials Group study BR. 24: A randomized, double-blind phase II trial of carboplatin (C) and paclitaxel (P) with either daily oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo, in patients with advanced non-small-cell lung cancer. J Clin Oncol 27:15s, 2009 (suppl; abstr 3527)
23. Hurwitz H, Douglas P, Middleton J, et al: Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV). J Clin Oncol 28:15s, 2010 (suppl; abstr 3039)
24. Jain L, Sissung TM, Danesi R, et al: Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res 29:95, epub 2010
25. Radaideh S, Gerber D, Dunphy F, et al: Association of hypertension (HTN) and clinical outcome in a phase II trial of cisplatin (C), pemetrexed (P), and bevacizumab (B) in patients (pts) with untreated malignant mesothelioma. J Clin Oncol 28, 2010 (suppl; abstr e18012)
26. Rini B, Schiller J, Fruehauf J, et al: Association of diastolic blood pressure (dBP) > 90 mmHg with overall survival (OS) in patients treated with axitinib (AG-013736). J Clin Oncol 26:163s, 2008 (suppl; abstr 3543)
27. Zee Y, Murukesh N, Kumaran G, et al: Hypertension (HTN) and proteinuria (PTN) as biomarkers of efficacy in antiangiogenic therapy for metastatic colorectal cancer (mCRC). J Clin Oncol 28, 2010 (suppl; abstr e13580)
28. McShane LM, Altman DG, Sauerbrei W, et al: Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97:1180-1184, 2005 (Pubitemid 41258223)
29. McGuire WL, Tandon AK, Allred DC, et al: How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst 82:1006-1015, 1990 (Pubitemid 20204970)
30. Rugo HS, Stopeck AT, Joy AA, et al: Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. J Clin Oncol 29:2459-2465, 2011